Madrid, Spain — October 30, 2025 — Veos Pharmaceuticals S.L., a Spain-based biotechnology company pioneering natural innovations for health and sustainability, has won Third Prize at the 9th China (Shenzhen) International Innovation & Entrepreneurship Competition (IEIC) — Barcelona Division — and has been selected to advance to the Industrial Phase in Shenzhen, China.

The recognition highlights ThymoTropin™, Veos Pharma's breakthrough natural dual-action myostatin inhibitor and TRPV3 activator, a clinically validated, non-hormonal innovation that enhances muscle strength, endurance, and metabolic health. ThymoTropin™ addresses muscle loss associated with aging, GLP-1 treatments, and chronic disease — positioning Veos as a global leader in muscle health biotechnology.

"Being recognized among the top three companies and moving forward to the Shenzhen industrial phase represents a major milestone for Veos. It validates our vision of bringing scientifically proven, sustainable solutions from Spain to the global market — from health to agriculture and environmental biotechnology." — Dr. Bassam Damaj, CEO and Co-Founder of Veos Pharmaceuticals

The Shenzhen Industrial Phase will provide Veos with access to strategic investors, industrial partners, and Chinese market expansion opportunities, supporting the company's plan to scale ThymoTropin™ and other Veos technologies across Asia.

A Portfolio Spanning Health, Food, Water, Agriculture & Industry

Founded in 2022 and profitable since 2024, Veos Pharmaceuticals develops a portfolio of innovations spanning:

• ThymoTropin™ — natural muscle health biotechnology
• VEOX-Preserve™ — food and beverage preservation
• OliQuell™ — water treatment and odor control
• BioPropello™ — sustainable agriculture and soil enhancement
• OleoSorb™ — oil absorption reduction technology

Veos operates across Europe and North America with over 40 commercial products.

For more information, visit www.veospharma.com or contact us at the details below.